🇺🇸 FDA
Patent

US 11787796

Plasma Kallikrein inhibitors and uses thereof

granted A61PA61P29/00A61P9/00

Quick answer

US patent 11787796 (Plasma Kallikrein inhibitors and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P29/00, A61P9/00